Martín, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Ciruelos, E. M., Muñoz, M., Bermejo, B., Margelí, M., Csöszi, T., Antón, A., Turner, N., Casas, M. I., Morales, S., Alba, E., Calvo, L., de la Haba-Rodríguez, J., Ramos, M., Murillo, L., Santaballa, A., Alonso-Romero, J. L., Sánchez-Rovira, P., Corsaro, M., Huang, X., Thallinger, C., Kahan, Z., & Gil-Gil, M. (2022). overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. European journal of cancer, 168, 12–24. http://access.bl.uk/ark:/81055/vdc_100155020454.0x000022